MedTrace Logo

High-Intensity Interval Training and Intermittent Fasting on Body Composition and Physical Performance in Active Women

NCT04404413 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2020-05-27

No results posted yet for this study

Summary

The objective of this study is to compare the body composition and physical performance effects of HIIT, with or without intermittent fasting intervention in active women. Fourteen active normal weight women aged 18-35 participated in the study. The effects of 2x8 weeks without (HIIT) or with (HIIT+IF) intermittent fasting caloric restriction (20% reduction in weekly energy intake) on body composition and performance (Hand-grip strength, Counter movement jump, Wingate Anaerobic 30 s Cycling Test), were compared. There were two weeks in between both phases when they did not perform the scheduled activity, so as not to alter the experimental phase.

Conditions

  • Body Composition
  • Physical Performance
  • Intermittent Fasting

Interventions

BEHAVIORAL

Intensity interval training (HIIT)

2x8 weeks of high-intensity interval training (HIIT)

BEHAVIORAL

Intensity interval training (HIIT) + intermittent fasting

2x8 high-intensity interval training with (HIIT+IF) intermittent fasting caloric restriction (20% reduction in weekly energy intake).

Sponsors & Collaborators

  • Universidad Católica San Antonio de Murcia

    collaborator OTHER

  • University of Alicante

    lead OTHER

Study Design

Allocation
NA
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-09-01
Primary Completion
2019-09-11
Completion
2020-03-01

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04404413 on ClinicalTrials.gov